Vol. 22, Issue 1, 2022September 14, 2022 CDT
ccby-4.0
The U.S. Drug Price Impasse: Regulation, Innovation, and Public Health
The U.S. Drug Price Impasse: Regulation, Innovation, and Public Health
prescription drug pricesdrug pricingMedicareMedicare Part Daffordable caredrug pricedrug price hikes
Articles in Vol. 22, Issue 1, 2022
Vol. 22, Issue 1, 2022
- Norms Reborn: Controversies and Challenges for the Future of Reproductive TechnologiesValerie Gutmann Koch
- Eroding Lines in Embryo Research and Abortion–Contradictory Slippery SlopesSonia M. Suter
- The U.S. Drug Price Impasse: Regulation, Innovation, and Public HealthCareen Ghazal
- The Ethical Use of Observation Units: Empowering Physician Autonomy for Patient Placement DecisionsJulie L. CampbellKathy LeeEmily Mann
- The 14-Day Embryo Rule: A Modest ProposalHenry T. Greely
- Setting The Price of Fertility: Egg Donor Compensation Following Kamakahi v. American Society For Reproductive MedicineBailey K. Sanders
- Segmented Innovation in the Legalization of Mitochondrial Transfer: Lessons from Australia and the United KingdomMyrisha S. Lewis
- Egg-Freezing, Uterine Transplants, and In Vitro Gametogenesis: Disruptive or Normalizing Reproductive Technologies?Radhika Rao
- Prohibited Medical Autonomy by Religious Freedom: The Unconstitutionality of the Texas Advance Directives Act and a Bioethical ConundrumDanielle A. Giaccio
Careen Ghazal, The U.S. Drug Price Impasse: Regulation, Innovation, and Public Health, 22 HOUS. J. HEALTH L. & POL’Y 275 (2022).